Paul D. Rubin is a partner based in the Washington, D.C. office and is the Co-Chair of the firm’s Healthcare & Life Sciences Group and the Chair of the FDA Regulatory practice. His practice focuses on FDA/FTC regulatory matters.
Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues ranging from strategic regulatory counseling to complex compliance and enforcement matters - including the representation of companies and individuals under investigation by FDA’s Office of Criminal Investigations (OCI). He also routinely conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions.
Mr. Rubin also has a substantial FTC practice advising clients on complex advertising/promotion, cybersecurity, and privacy-related issues, including compliance with the Restore Online Shoppers Confidence Act (ROSCA) and Fair Credit Reporting Act (FCRA). In addition to his FTC counseling practice, Mr. Rubin represents companies under FTC investigation in responding to civil investigative demands (CIDs) and negotiating FTC settlements/consent decrees. Mr. Rubin also has substantial expertise handling disputes before the National Advertising Division of the BBB National Programs (NAD) and advertising lawsuits under Section 43(a) of the Lanham Act. Mr. Rubin also advises consumer product companies on CPSC-related compliance, including Section 15(b) submissions and “Fast Track Recalls.”
Mr. Rubin is recognized as a leading practitioner by Chambers USA (2024) for Regulatory Healthcare, where clients note that “he is a master of divining practical solutions for complex problems.” He is also recognized by The Legal 500 US (2024) for Life Sciences and Advertising and Marketing Litigation. According to clients, he is “an outstanding thought leader in matters involving FDA and FTC regulation.” He has been ranked as a Life Sciences Star by LMG Life Sciences every year since the editorial was first published in 2013 and has been an LMG Life Sciences’ “Regulatory Attorney of the Year” finalist in 2019, 2022, and 2024.
Mr. Rubin is a co-author of the leading treatise on advertising law, The Law of Advertising, Marketing and Promotion. Mr. Rubin is also a contributing author to the Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2023) and the co-author of various articles, including “After Chevron: FDA Regulations In The Crosshairs,” Law360 (July, 2024); “National Association of Attorneys General’s 2023 Consumer Protection Spring Conference,” NYU Compliance & Enforcement Blog (July, 2023); “CFPB Advisory on Placement Practices May Have Broader Market Implications,” NYU Compliance & Enforcement Blog (March, 2023); “Model Destruction – The FTC’s Powerful New AI and Privacy Enforcement Tool,” NYU Compliance & Enforcement Blog (March, 2022); “A New Era of Federal Trade Commission (“FTC”) Privacy and Cybersecurity Oversight: Top Ten Things Companies Should Know When Assessing FTC Compliance and Exposure,” NYU Compliance & Enforcement Blog (January, 2022); “What Stablecoin Industry Can Expect From Congress In 2022,” Law360 (January, 2022); “Infringing Influencers? Federal Judge Says Sponsored Blogger Can Face Trademark Infringement Liability,” IP Watchdog (August, 2021); “Lessons From Federal Fraud Charges Against UBiome,” Law360 (April, 2021); “The American Rescue Plan Act of 2021: Pharmaceutical Industry Impact,” Pharm Exec (March, 2021); “Destruction Emerges as a Powerful Enforcement Measure for AI: FTC Requires Company to Delete Models Trained with Improperly Utilized Consumer Data,” NYU Compliance & Enforcement Blog (January, 2021); “Debevoise & Plimpton Discusses State Marijuana Initiatives and Financial Institutions,” Columbia Blue Sky Blog (November, 2020); “Trump's Drug Pricing Order Is More Bark Than Bite,” Law360 (September, 2020); “Providers, Investors Need Clear Post-Covid Telehealth Picture,” Bloomberg Law (September, 2020); “Expert Analysis: COVID-19 Raises Unique Issues For Health, Life Sciences Cos.,” Law360 (March, 2020); “Insight: The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies,” Bloomberg Law (November, 2019); “Expert Analysis: Drugmaker Fine Shows SEC's Renewed Disclosure Focus,” Law360 (August, 2019); “How Life Sciences Cos. Can Prepare for Legal and PR Crises,” Law360 (December, 2018); “A Look at Recent Efforts to Contain Health Care Costs,” Law360 (January, 2018); and “How Tax Reform Could Impact the Health Care Industry,” Law360 (November, 2017). He is also a frequent lecturer on FDA/FTC law and has guest lectured at the University of Pennsylvania Law School.
Mr. Rubin joined Debevoise in 2017. He earned his J.D. cum laude from the University of Pennsylvania Law School in 1992. He received a B.S. in Economics magna cum laude from the University of Pennsylvania Wharton School of Business in 1989.